Product information and disease description / Product description / Product informationIndication3 evidence topics · 3 sourcesInvestigational status: no approved indication“The product is not authorised anywhere in the European Community.” (opens the source at this quote in a new tab)CopyFlag“To date, we have not generated any revenues from the commercial sale of approved drug products, and we do not expect to generate substantial revenue for at least the next few years.” (opens the source at this quote in a new tab)CopyFlagProposed indication: patients aged 2 years and older with Rett syndrome“The TSHA-102 clinical development program is designed to support the potential future approval for a broad population of patients aged 2 years and older with Rett syndrome through an efficient and rigorously designed pathway.” (opens the source at this quote in a new tab)CopyFlag“In close collaboration with the U.S. Food and Drug Administration, Taysha designed the TSHA-102 pivotal program so that efficacy data from the REVEAL Pivotal Trial in participants aged 6 to <22 years who have reached developmental plateau can be used to represent patients aged 2 to <6 years, while safety data in younger children are generated through the separate ASPIRE Trial to support a broad label for TSHA-102.” (opens the source at this quote in a new tab)CopyFlag“We also obtained written alignment from the FDA on an extrapolation approach in a separate safety-focused study, which we refer to as the ASPIRE trial, and the data for inclusion in the planned BLA submission to enable potential broad labeling of TSHA-102 for patients aged ≥2 years with Rett syndrome.” (opens the source at this quote in a new tab)CopyFlagPopulation studied: females with a MECP2 loss-of-function mutation“We are evaluating TSHA-102 for the treatment of females with Rett syndrome in our REVEAL and ASPIRE clinical trials.” (opens the source at this quote in a new tab)CopyFlag“The REVEAL Phase 1/2 Adolescent and Adult Trial, also known as Part A, is a first-in-human, open-label, randomized, dose-escalation and dose-expansion study evaluating the safety and preliminary efficacy of TSHA-102 as a single lumbar intrathecal administration in adolescent and adult females aged 12 years and older with Rett syndrome due to loss-of-function mutation in the methyl-CpG binding protein 2, or MECP2, gene.” (opens the source at this quote in a new tab)CopyFlag